<DOC>
	<DOCNO>NCT01197885</DOCNO>
	<brief_summary>IMAB362 monoclonal antibody specific gastric low esophageal adenocarcinoma . Preclinically IMAB362 show inhibit tumor growth kill cancer cell indirect ( complement-dependent cytotoxicity , antibody-dependent cellular cytotoxicity ) direct mechanism ( antiproliferative proapoptotic effect ) . The aim phase II study establish efficacy safety multiple dos IMAB362 monotherapy patient suffer metastatic , refractory recurrent adenocarcinoma stomach low esophagus .</brief_summary>
	<brief_title>Efficacy Safety Study Multiple Doses IMAB362 Patients With Advanced Gastroesophageal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Metastatic , refractory recurrent disease advance adenocarcinoma stomach lower esophagus proven histology CLDN18.2 expression biopsy material cancer confirm immunohistochemistry At least 1 measurable site disease accord RECIST criterion Less 3 week since prior chemoor radiation therapy Other concurrent anticancer therapy Concurrent anticoagulation vitamin K antagonists Therapeutic dos Heparin ( prophylactic dos accept ) Uncontrolled severe illness</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>